Alzheimer’s disease is the most common form of dementia, affecting over 35 million people worldwide. It is generally assumed that the clumping of beta-amyloid protein causes neuronal loss in patients. Medication focuses on reducing beta-amyloid 42, one of the most common proteins and the most harmful. Researchers in the Netherlands are refining the current approach.